Reblozyl Tops $2.3B Sales, Heightening Pressure on Geron’s Rytelo Growth
Reblozyl crossed $2.3 billion in annualized sales and has positive Phase 2 ex-U.S. data with upcoming presentations and potential new geographic approvals, expanding its thalassemia and MDS indications. This intensifies competition for Geron’s Rytelo, which generated $183.6 million in 2025 and forecasts $220–240 million in 2026.
1. Reblozyl’s Strong Sales and Pipeline
Bristol Myers’ Reblozyl has surpassed $2.3 billion in annualized sales driven by first-line U.S. myelodysplastic syndrome demand and robust international launches. A Phase 2 ex-U.S. registrational trial met all primary and key secondary endpoints in alpha-thalassemia, boosting hemoglobin levels and reducing transfusion needs, with full data slated for an upcoming medical meeting.
2. Competitive Pressure on Geron’s Rytelo
Geron’s Rytelo posted $183.6 million in sales during 2025 and anticipates $220–240 million in 2026, but Reblozyl’s expanded MDS and thalassemia indications could erode Rytelo’s market share. Additional approvals for Reblozyl in new geographies are likely to intensify competition for treatment of transfusion-dependent anemia.
3. Future Outlook and Market Dynamics
Reblozyl’s push into RS-negative MDS and potential approvals in Asia and Europe signal growing pressure on anemia drug markets. Geron will need to leverage pricing strategies, real-world evidence and differentiation efforts to uphold Rytelo’s growth trajectory.